skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
Glioblastoma Cancer Vaccine ERC1671 (Code C107502)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Glioblastoma Cancer Vaccine ERC1671

Definition: A cancer vaccine composed of a combination of autologous glioblastoma (GBM) tumor cells, allogeneic GBM tumor cells, generated from three different GBM donor cancer patients, and the lysates of all of these cells, with potential antineoplastic activity. Upon intradermal administration of GBM cancer vaccine ERC1671, the mixture of the autologous and allogeneic cells and lysates stimulates the immune system to mount a cytotoxic T-lymphocyte (CTL) response against GBM-associated antigens, which leads to the destruction of glioblastoma cells.

Display Name: Glioblastoma Cancer Vaccine ERC1671

Label: Glioblastoma Cancer Vaccine ERC1671

NCI Thesaurus Code: C107502 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: CL451748  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
Glioblastoma Cancer Vaccine ERC1671

External Source Codes: 
PDQ Closed Trial Search ID 751319
PDQ Open Trial Search ID 751319 (check for NCI PDQ open clinical trial info)

Other Properties:
     Name Value (qualifiers indented underneath)
code C107502
Contributing_Source CTRP
Semantic_Type Cell
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom